State Street Corp Bio Xcel Therapeutics, Inc. Transaction History
State Street Corp
- $2.25 Trillion
- Q2 2024
A detailed history of State Street Corp transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 124,749 shares of BTAI stock, worth $74,849. This represents 0.0% of its overall portfolio holdings.
Number of Shares
124,749
Previous 464,908
73.17%
Holding current value
$74,849
Previous $1.31 Million
87.87%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding BTAI
# of Institutions
78Shares Held
7.26MCall Options Held
101KPut Options Held
205K-
Armistice Capital, LLC New York, NY2.99MShares$1.79 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA970KShares$582,2580.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$264,4110.0% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$160,0310.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA204KShares$122,1690.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $16.8M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...